Amgen Inc. (NASDAQ:AMGN) Receives Consensus Rating of “Hold” from Analysts

Amgen Inc. (NASDAQ:AMGN) has earned an average recommendation of “Hold” from the thirty analysts that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $385.25.

Several equities analysts recently weighed in on AMGN shares. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a report on Friday, June 5th. Oppenheimer reaffirmed an “outperform” rating on shares of Amgen in a report on Wednesday, September 23rd. Sanford C. Bernstein upped their target price on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Weiss Ratings raised Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 6th. Finally, Bank of America raised their price target on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th.

Amgen Price Performance

Shares of AMGN stock opened at $423.64 on Wednesday. The stock has a 50-day moving average price of $408.35 and a 200 day moving average price of $369.43. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $229.03 billion, a price-to-earnings ratio of 26.33, a PEG ratio of 3.02 and a beta of 0.43. Amgen has a 12 month low of $274.02 and a 12 month high of $447.03.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts expect that Amgen will post 22.94 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s dividend payout ratio is 62.65%.

Insiders Place Their Bets

In related news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by corporate insiders.

Institutional Trading of Amgen

Several hedge funds have recently added to or reduced their stakes in the company. QRG Capital Management Inc. boosted its position in shares of Amgen by 14.3% in the second quarter. QRG Capital Management Inc. now owns 107,906 shares of the medical research company’s stock valued at $36,197,000 after acquiring an additional 13,523 shares during the period. Envestnet Portfolio Solutions Inc. grew its stake in shares of Amgen by 15.0% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 24,293 shares of the medical research company’s stock valued at $8,797,000 after acquiring an additional 3,169 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Amgen by 19.2% during the second quarter. Envestnet Asset Management Inc. now owns 2,023,566 shares of the medical research company’s stock worth $732,774,000 after acquiring an additional 326,260 shares during the period. State Street Corp raised its stake in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. Finally, Premier Financial Group bought a new stake in Amgen in the 2nd quarter valued at about $139,000. 76.50% of the stock is owned by institutional investors and hedge funds.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.